Royalty Report: Drugs, Delivery, Therapeutic – Collection: 240617

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Delivery
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 240617

License Grant
Licensor shall exclusively manufacture and supply to Licensee, its Affiliates and Partners, and Licensee, its Affiliates and Partners shall exclusively purchase from Licensor 100% of their requirements for Product in the Territory during the Term.

Licensor grants a nonexclusive license under the Licensor Patent Rights,as defined in the Scale-Up Agreement between the parties, and Licensor Know-How to use, sell. offer for sale, and import Product in the Territory manufactured by or for Licensor under this Agreement.

License Property
The parties have developed a press-and-breathe inhaler containing a pressurized aerosol canister with a metered dose valve filled with a formulation of the compound levalbuterol tartrate.

Compound shall mean the compound known as levalbuterol, including any salt, ester, solvate, clathrate, or polymorph thereof.

Active Ingredient shall mean micronized levalbuterol hemitartrate.

Product shall mean a press-and-breathe inhaler containing a pressurized aerosol canister with a metered dose valve as developed under the Scale-up Agreement containing Active Ingredient, oleic acid, ethanol, and 1,1.1.2-tetratluoroethane as set forth in the Specifications and prepared in accordance with the Specifications.

Field of Use
The purpose is to introduce to the pharmaceutical marketplace an aerosol product for inhalation.

IPSCIO Record ID: 203483

License Grant
Licensor grants a worldwide, non-exclusive license under the Licensor Patent Rights and Know-How to use, sell, offer for sale, and import Licensed Product manufactured by or for Licensor under this Agreement or a subsequent Supply Agreement. Licensee shall have the right to submit for listing on the FDA Orange Book patents under Licensor Patent Rights that cover Licensed Product.
License Property
Licensor has experience and technology in the formulation, scale-up, and manufacture of pharmaceutical products in aerosols for inhalation therapy.

The Product means a press-and-breathe inhaler containing a pressurized aerosol canister with a metered dose valve filled with a formulation of the Compound that Licensee has selected having the formulation, and meeting the Specifications.

The term Licensed Product means Product containing the Compound levalbuterol tartrate. Tartrate shall mean any tartaric acid salt, including but not limited to D-tartrate, L-tartrate, and DTL tartrate. in any stoichiometry, including but not limited to levalbuterol hemitartrate.

Licensor Confidential Information means confidential information disclosed by Licensor to Licensee in the course of and pursuant to this Agreement relating to aerosol inhalation, or aerosol compositions, including the specifications and chemistry of aerosol formulations of Compound developed by Licensor or its Affiliates; metered dose inhaler devices and their specifications; the methods and techniques used by Licensor to manufacture aerosol inhalers and metered dose devices; and confidential information directly or indirectly provided by Licensor to assist Licensee to obtain a license or approval permitting the sale of Licensed Product, including clinical results for metered dose devices.

Licensor Patent Rights means all patents and patent applications that are owned or controlled by Licensor or an Affiliate thereof and that cover manufacture, use, or sale of Licensed Product, including but not limited to certain of those patents claiming benefit of priority to, or having a substantially identical disclosure as, Great Britain application GB8828477, U.S. application 442,119, and, U.S. application 92,001, and all applicable continuations, continuations-inpart, divisionals, extensions, supplemental protection certificates, utility models, reissues, and reexaminations thereof.

Field of Use
The product is being developed to market for inhalation therapy.

IPSCIO Record ID: 315809

License Grant
Licensor grants under the Licensor Technology in the U.S.
–   an exclusive license, with the right to sublicense, to research, develop, import, use, market, sell, have sold, offer for sale and otherwise commercialize the Product in the Field in the U.S., and
–   a co-exclusive license, with the right to sublicense, to manufacture and have manufactured the Product for the purposes of researching, developing, importing, using, marketing, selling, having sold, offering for sale and otherwise commercializing the Product in the Field in the U.S.; and,
–   a non-exclusive license, with the right to sublicense, solely and to the extent needed to conduct clinical and non-clinical development activities with respect to the Product in the Field outside the U.S.
License Property
Licensor is a pharmaceutical development company focused on the research, development, manufacturing and commercialization of novel proprietary products for the acute treatment of central nervous system disorders based on its proprietary technology, the Staccato® system, and has developed and obtained FDA approval for a drug-device combination product that is comprised of Loxapine (as defined hereinafter) delivered by a Staccato Device, and approved under the trade name Adasuve. Licensor owns or controls certain patents, know-how and other intellectual property relating to the Staccato Device and Product.

Product shall mean the drug-device combination product that is comprised of Loxapinc delivered by the Staccato Device, which has been or is during the Term approved by the FDA in the U.S., which form of product is currently designated as Adasuve®.

Staccato Device shall mean any hand-held, fixed-dosage device for the administration of API(s), which relies on Licensors proprietary heat package and stainless steel substrate to rapidly heat and create a condensation vaporized aerosol of APl(s) that allows the delivery of API(s) through deep lung inhalation, where the device is known as or based on, but may or may not be referred to, as the Staccato® system.

The patents relate to the Delivery of antipsychotics through an inhalation route.

Field of Use
ADASUVE (loxapine) is an inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.